PCSK9: the new lipid target in preventive cardiology?
ESC Amsterdam, August 31, 2013Oct. 4, 2013
The symposium PCSK9: the new lipid target in preventive cardiology? was held at the congress of the European society of Cardiology (ESC) in Amsterdam on August 31, 2013.
- Understand the unmet need for additional LDL-C-lowering therapies beyond current optimal statin-based therapy as a strategy for addressing lipid-related CV risk in patients with FH
- Understand the mechanisms and potential applications of emerging therapies to lower LDL through novel approaches that can be used in combination with statin therapy
- Describe the potential impact of PCSK9-based therapies in development in patients who require additional LDL-C reduction
- Compare and evaluate evidence from recent clinical trials of novel agents in clinical development and assess their impact on lipids and cardiovascular risk
Familial Hypercholesterolemia: Why are we not reaching goals in these patients?
John Kastelein, Academic Medical Center, Amsterdam, Netherlands
PCSK9 inhibition: Mechanistic insights into a new therapeutic approach for the lowering of LDL-c
Gilles Lambert, University of Nantes Medical School, Nantes, France
Monoclonal antibodies that target PCSK9: What the first clinical trial data are telling?
Evan Stein, Metabolic and Atherosclerosis Research Center, Cincinnati, USA
The roadmap of PCSK9 inhibitors towards the clinic: An overview of current development programs & outcome studies
Henry Ginsberg, Columbia University Medical Center, New York